Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B
NCT07595159Phase 1Completed
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial of BW-20507 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoint: Number of subjects with adverse events (AEs) and serious adverse events (SAEs) at 12 weeks. Started Jun 2024; status: completed.
02
Drugs
BW-20507
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07595159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595159.